TB4 vs TB500 peptide: what's actually different

Last updated 2026-07-24

What is the actual difference between TB4 and TB500?

Thymosin beta-4 (TB4) is a small, naturally occurring protein made of 43 amino acids. It's found throughout mammalian tissue and blood, and it's one of the most abundant proteins in the actin-binding thymosin family. Cells use it to regulate actin, the structural protein that lets cells move and change shape, which is why it shows up in wound healing and tissue repair research. TB-500 is not the same molecule. It's a name attached to synthetic peptide products sold online, and it's generally described as a shorter fragment built around the active region of TB4, most commonly the 17-23 amino acid stretch. A 2012 analytical chemistry paper actually synthesized and characterized this N-terminal acetylated 17-23 fragment specifically because it had turned up in products sold as "TB-500" and regulators wanted to know what was really in the vial ^[1]. So the honest framing is: TB4 is the parent protein nature makes. TB-500 is a commercial name loosely tied to a fragment or analog of it. Products sold under that name aren't guaranteed to contain full-length TB4, and sloppy marketing copy treats the two as interchangeable when they aren't chemically identical.

Is TB-500 the same as thymosin beta-4?

No, not in the strict chemical sense, even though the names get used interchangeably online. Full-length thymosin beta-4 is 43 amino acids. TB-500 as characterized in analytical chemistry work is tied to a 7-amino-acid fragment (residues 17-23) with an acetylated N-terminus, which is a different, much smaller molecule than the intact protein ^[1]. A 2024 chromatography and mass spectrometry paper went further and did simultaneous quantification of TB-500 and its metabolites in both in-vitro experiments and live rats, screening the results against wound healing activity ^[2]. That study treats TB-500 as its own analyte, distinct from native TB4, which tells you the analytical chemistry field itself doesn't collapse the two into one thing. For a longer side-by-side on molecular structure and mechanism, see our dedicated thymosin beta 4 vs TB 500 comparison.

What does the research actually show for TB4 and TB500?

Almost everything published is preclinical. That means cell culture studies and animal models, not controlled human trials. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons' Global Research & Reviews looked at therapeutic peptides in orthopaedics broadly, covering applications, challenges, and where the field needs to go next, and it treats peptides like TB-500 as an emerging category still working through basic development questions rather than an established clinical tool ^[3]. A companion piece in The American Journal of Sports Medicine, published as a primer for orthopaedic and sports medicine physicians on injectable peptide therapy, frames these compounds the same way: physicians need a working understanding of them because patients are already asking about them, not because there's a deep human trial base behind them ^[4]. A 2026 paper in Sports Medicine (Auckland) specifically reviewed safety and efficacy data for approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, again grouping unapproved products like TB-500 as a separate, less-studied tier compared to approved pharmaceuticals ^[5]. Separately, thymosin beta-4 itself (the native protein, not TB-500 specifically) has been studied in gerontology research. A 2026 review in Frontiers in Aging covers therapeutic peptides in gerontology, including mechanisms relevant to healthy aging, positioning TB4-family peptides as a mechanism-level research interest rather than an approved anti-aging therapy ^[6].

Does TB-500 show up in a wound healing lab test?

Yes, at least in vitro. The 2024 chromatography paper that quantified TB-500 and its metabolites also ran wound healing screening assays in-vitro alongside the analytical work, meaning they weren't just measuring how much TB-500 was present but also testing what it did to cells in a dish ^[2]. That's a meaningful data point, but it's a lab dish, not a person with a torn tendon. Nobody should read "active in a wound healing assay" as "proven to heal your injury faster." It's evidence of biological activity worth studying further, nothing more.

Is TB-500 legal, and is it banned in sports?

TB-500 is not an FDA-approved drug. You won't find it in the Drugs@FDA database of approved drug products ^[7]. It also doesn't appear on FDA's lists of bulk drug substances that compounding pharmacies are allowed to use under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act ^[8][9]. Those lists (21 CFR 216.23 and 216.24) define what a compounder can legally source and combine into a prescription; a substance not on them, or not the subject of an active FDA nomination review, sits in a gray zone for compounding purposes ^[10][11]. For competitive athletes, the picture is unambiguous: TB-500 is treated as a prohibited peptide under anti-doping rules, and it's been the subject of active detection method development for over a decade. A 2012 paper in the Journal of Chromatography A built a liquid chromatography-mass spectrometry method specifically to detect TB-500 in equine urine and plasma for doping control ^[12]. Human anti-doping labs have followed the same path: a 2014 paper in the Journal of Pharmaceutical and Biomedical Analysis reviewed analytical approaches for detecting emerging therapeutics and non-approved drugs, including TB-500, in human doping controls ^[13]. If you compete under WADA or a similar body's rules, using TB-500 is a straightforward violation risk, not a gray area.

How hard is TB-500 to detect in a drug test?

Harder than a lot of small molecules, but labs have built specific workarounds. Peptides under roughly 2,000 daltons are tricky for standard doping panels, so a 2016 paper in the Journal of Separation Science focused on simplifying and expanding screening for peptides under 2 kDa using direct urine injection combined with liquid chromatography and ion mobility mass spectrometry ^[14]. Separately, a 2016 Drug Testing and Analysis paper worked out solid-phase extraction methods for small biologically active peptides from human urine using cartridges and microelution 96-well plates, which is the sample-prep step that makes downstream detection reliable ^[15]. There's also a practical wrinkle: some peptides stick to lab plasticware and glassware before they even reach the detector. A 2017 paper in Analytical Biochemistry specifically studied adsorption effects for doping-relevant peptides including TB-500, alongside Insulin Lispro, Synacthen, and GHRP-5, because a peptide that adsorbs to tubing can produce a falsely low reading if the method isn't corrected for it ^[16]. Anti-doping chemists have also tested TB-500 detection in horse plasma using LC-MS across a panel of seven bioactive peptides ^[17], and built in vitro metabolism models using proteolytic enzymes, human serum, and liver and kidney microsomes to figure out what TB-500 breaks down into inside the body, since testing for a metabolite can sometimes catch what testing for the parent compound misses ^[18][19]. None of this is DIY territory. It's a genuine analytical chemistry problem that multiple labs have spent over a decade refining.

How do TB4 and TB500 compare side by side?

Can you buy TB-500 by itself?

No. There is no standalone TB-500 product moving through a legitimate pharmacy channel. Where it's available through a provider-reviewed route, it's dispensed as a BPC-157/TB-500 blend, prepared by a compounding pharmacy under a clinician's oversight, not sold as an isolated TB-500 SKU. TB-500 Co works with that model: a provider reviews the case, and if a compounded blend is appropriate, a licensed pharmacy partner fills it. That's a meaningfully different thing than ordering an unregulated "research peptide" vial online with no clinician involved and no chain of custody on what's actually in it. If you're deciding whether any of this is worth pursuing at all, start with the safety question before the sourcing question. See is TB-500 safe for the honest risk picture, and TB-500 for sale for how legitimate versus gray-market sourcing actually differs.

What about dosing, is it the same for TB4 and TB500?

There's no FDA-approved dosing for either, because neither has gone through the human trial process that produces an approved label with a validated dose. Anything you see quoted as a "TB-500 protocol" online is coming from anecdotal practice or preclinical animal dosing extrapolated by non-experts, not from a peer-reviewed human dose-finding study. The papers cited in this article are almost entirely mechanism, detection, and analytical chemistry work, not clinical dosing trials ^[3][4][5]. If a provider decides a compounded BPC-157/TB-500 blend is appropriate for your situation, dosing should come from that clinician based on your case, not from a forum post. For a general sense of how these protocols are typically discussed and what ranges show up in practice, see TB-500 dosage and the TB-500 dosage calculator, but treat both as educational starting points for a conversation with a provider, not a substitute for one.

Why do people confuse TB4 and TB500 so often?

Mostly marketing shorthand. Early research and patent literature on thymosin beta-4 for wound healing generated genuine scientific interest, and "TB-500" got adopted as a catchier commercial name that borrows credibility from that research even though what's actually in many products is a shorter fragment, not the full native protein ^[1]. Once a name sticks in supplement and research-chemical marketing, it tends to get used for anything vaguely related, and TB-500 vs TB4 vs thymosin beta-4 fragment all get flattened into one interchangeable term by sellers who either don't know the difference or don't care. The analytical chemistry community has had to work around exactly this confusion. Multiple papers cited here exist specifically because regulators, anti-doping labs, and researchers needed to nail down what molecule is actually in a product sold as TB-500, separate from what's in the scientific literature about native thymosin beta-4 ^[1][2]. If a seller's page uses "TB4" and "TB-500" as pure synonyms with no acknowledgment of the fragment-versus-full-protein distinction, that's a signal they're working from marketing copy, not the primary literature. Our main TB-500 overview covers the full mechanism picture if you want the deeper background on what native TB4 actually does in tissue repair.

Frequently asked questions

Is TB4 the same thing as TB-500?

No. TB4 (thymosin beta-4) is the native 43-amino-acid protein your body makes naturally. TB-500 is a commercial name for a synthetic product, typically built around a shorter fragment of that protein, most often the 17-23 amino acid region. They're related but not chemically identical ^[1].

Which has more human research, TB4 or TB-500?

Neither has a strong human trial record. Native TB4 shows up more in mechanism-level research, including gerontology studies on aging biology ^[6]. TB-500 as a commercial product is covered mainly in orthopaedic and sports medicine reviews that describe it as preclinical and still developing ^[3][4][5].

Can you buy TB-500 as a standalone product?

No legitimate standalone TB-500 product exists through a pharmacy channel. Where it's available through a provider-reviewed route, it's dispensed only as part of a compounded BPC-157/TB-500 blend prepared by a licensed pharmacy, not sold as an isolated TB-500 SKU.

Is TB-500 FDA approved?

No. It doesn't appear in the FDA's Drugs@FDA database of approved drug products ^[7], and it's not on the 503A or 503B bulk drug substance lists that govern what compounding pharmacies can legally use ^[8][9].

Is TB-500 banned in sports?

Yes, it's treated as a prohibited peptide in competitive sport. Anti-doping labs have built specific LC-MS detection methods for TB-500 in both human and equine testing for over a decade, which reflects how seriously anti-doping bodies treat it ^[12][13].

Why is TB-500 hard to test for in a lab?

It's a small peptide, under roughly 2,000 daltons, which standard drug-testing panels weren't originally built to catch well. Labs have developed specific methods, including direct urine injection with ion mobility mass spectrometry, to close that gap ^[14].

Does TB-500 stick to lab equipment during testing?

Yes, this is a documented issue. A 2017 Analytical Biochemistry study found adsorption effects for TB-500 and several other doping-relevant peptides, meaning the peptide can bind to tubing or plasticware and produce artificially low readings if methods aren't corrected for it ^[16].

What does the wound healing data on TB-500 actually show?

A 2024 study quantified TB-500 and its metabolites in vitro and in rats, then screened the results against wound healing activity in cell-based assays ^[2]. That's real evidence of biological activity in a lab setting, but it's not a human clinical trial and shouldn't be read as proof of effectiveness in an injured person.

Is there an approved dose for TB-500 or TB4?

No. Neither has an FDA-approved label with a validated human dose. Any dosing protocol you see online comes from anecdotal or extrapolated sources, not peer-reviewed clinical trials. If a provider recommends a compounded blend, dosing should come from that clinician's assessment of your case.

Are TB4 and TB-500 metabolized the same way in the body?

Not established as identical. Researchers have specifically built in vitro metabolism models, using proteolytic enzymes, human serum, and liver/kidney microsomes, to characterize how TB-500 breaks down, treating it as its own analyte separate from native thymosin beta-4's biology ^[18][19].

Why do sellers use TB4 and TB-500 as interchangeable names?

Mostly marketing convenience. TB-500 borrows credibility from decades of thymosin beta-4 research, even though many products sold under that name are shorter fragments rather than the full native protein ^[1]. Sellers who treat the names as pure synonyms usually aren't working from the primary chemistry literature.

Should I worry about sourcing if I'm not a competitive athlete?

Sourcing still matters even outside sport. Because there's no standalone, FDA-approved TB-500 product, quality and identity depend entirely on the compounding pharmacy and provider oversight behind whatever blend you're considering, not on a retail label you can verify yourself.

Sources

1. Drug Testing and Analysis, 2012 (PMID 22962027): TB-500 products have been analytically tied to the N-terminal acetylated 17-23 fragment of thymosin beta-4, a synthesized and characterized fragment distinct from the full 43-amino-acid native protein.
2. Journal of Chromatography B, 2024 (PMID 38382158): A 2024 study simultaneously quantified TB-500 and its metabolites in vitro and in rats using UHPLC-Q-Exactive Orbitrap MS/MS, and screened results for wound healing activity in vitro.
3. Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, 2026 (PMID 41490200): A 2026 orthopaedic review covers therapeutic peptides' applications, challenges, and future directions, framing peptides like TB-500 as an emerging, still-developing category.
4. The American Journal of Sports Medicine, 2026 (PMID 41476424): A 2026 primer for orthopaedic and sports medicine physicians on injectable peptide therapy is aimed at clinician education given rising patient interest, not at documenting established clinical outcomes.
5. Sports Medicine (Auckland), 2026 (PMID 41966639): A 2026 review of safety and efficacy of approved versus unapproved peptide therapies for musculoskeletal injuries groups unapproved products like TB-500 as a distinct, less-studied tier.
6. Frontiers in Aging, 2026 (PMID 42021992): A 2026 gerontology review covers mechanisms and applications of therapeutic peptides, including thymosin beta-4 family peptides, for healthy aging research.
7. FDA, Drugs@FDA database: TB-500 does not appear as an FDA-approved drug product in the Drugs@FDA database.
8. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA maintains a list governing which bulk drug substances compounding pharmacies may legally use under Section 503A, and TB-500 is not on it.
9. FDA, Bulk Drug Substances Nominated for Use in Compounding (current list): FDA's current nominated bulk drug substances list tracks substances under review for compounding use.
10. 21 CFR 216.23, the final 503A Bulks List: 21 CFR 216.23 codifies the final list of bulk drug substances that may be used in compounding under Section 503A.
11. 21 CFR 216.24, the 503B Bulks List: 21 CFR 216.24 codifies the list of bulk drug substances that outsourcing facilities may use under Section 503B.
12. Journal of Chromatography A, 2012 (PMID 23084823): A 2012 LC-MS method was developed specifically to detect TB-500 in equine urine and plasma for doping control purposes.
13. Journal of Pharmaceutical and Biomedical Analysis, 2014 (PMID 24906629): A 2014 review of analytical approaches for detecting emerging therapeutics and non-approved drugs in human doping controls includes TB-500 as a target analyte.
14. Journal of Separation Science, 2016 (PMID 26578461): A 2016 method simplified and expanded screening for peptides under 2 kDa using direct urine injection, liquid chromatography, and ion mobility mass spectrometry.
15. Drug Testing and Analysis, 2016 (PMID 26472487): A 2016 study developed solid-phase extraction methods for small biologically active peptides from human urine using cartridges and microelution 96-well plates.
16. Analytical Biochemistry, 2017 (PMID 28887173): A 2017 study documented adsorption effects for doping-relevant peptides including TB-500, Insulin Lispro, Synacthen, and GHRP-5, which can cause falsely low test readings if uncorrected.
17. Analytical and Bioanalytical Chemistry, 2013 (PMID 23318763): A 2013 study performed doping control analysis of seven bioactive peptides, including TB-500, in horse plasma using LC-MS.
18. Journal of Peptide Science, 2015 (PMID 25469748): A 2015 paper developed in vitro models for metabolic studies of small peptide hormones relevant to sport drug testing.
19. Journal of Proteomics, 2016 (PMID 27569051): A 2016 comparison tested multiple in vitro model systems, including proteolytic enzymes, human serum, and liver/kidney microsomes, for metabolizing synthetic doping peptides.